GSK plc (GLAXF) stock
GLAXFOTCPharmaceutical PreparationsAlso trades as GSK
Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30
$24.74+0.30 (+1.21%)
Close on Oct 19, 2026Market cap $106.83BP/E 13.3Yield –
GSK EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
GSK's EV/EBITDA was 8.9× on Oct 19, 2026, against 13.1× a year earlier. Over the last 5 years it ranged from 7.7× to 17.9×, with a median of 9.6×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Oct 19, 2026 | 8.9× | −4.5 |
| 2025 | Dec 31, 2025 | 13.4× | +5.6 |
| 2024 | Dec 31, 2024 | 7.7× | −1.1 |
| 2023 | Dec 29, 2023 | 8.9× | −4.3 |
| 2022 | Dec 30, 2022 | 13.1× | −0.3 |
| 2021 | Dec 31, 2021 | 13.4× | +2.8 |
| 2020 | Dec 31, 2020 | 10.7× | −4.1 |
| 2019 | Dec 31, 2019 | 14.8× | −0.1 |
| 2018 | Dec 31, 2018 | 14.9× | −3.6 |
| 2017 | Dec 29, 2017 | 18.5× | +12.7 |
| 2016 | Dec 30, 2016 | 5.8× | – |